Mumbai, June 30, 2017: Pharma Major Glenmark Pharmaceuticals today said that the company has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets-5 mg and 10 mg, Solifenacin Succinate tablets are used for treatment of overactive bladder, company said in a filing with BSE. The company’s products are the generic version of Vesicare tablets, 5 mg and 10 mg of Astellas Pharma US Inc. According to IMS Health April 2017 sales data, the market for Vesicare tablets-5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. Glenmark’s current portfolio consists of 117 products authorised for distribution in the US marketplace, the company said, adding that it has 68 Abbreviated New Drug Applications (ANDA) pending with the USFDA
United News of India
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…
Nagpur, April 03, 2024: HCG Cancer Center Nagpur has launched a one-of-a-kind indigenous Asia`s first…